Drug Profile
PSI 7851
Alternative Names: PSI-7851Latest Information Update: 25 Aug 2010
Price :
$50
*
At a glance
- Originator Pharmasset
- Class Antivirals; Cell therapies; Nucleosides; Pyrimidine nucleosides
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 25 Aug 2010 Discontinued - Phase-I for Hepatitis C in USA (PO)
- 31 Jul 2009 Interim efficacy and adverse events data from a phase Ib trial in hepatitis released by Pharmasset
- 09 Jun 2009 Interim adverse events data from a phase Ia trial in healthy volunteers, and pharmacokinetic data, released by Pharmasset